Overview

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Status:
Terminated

Trial end date:
2019-07-16

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, multicenter study of the efficacy of UVADEX® (methoxsalen) Sterile Solution in conjunction with THERAKOS® CELLEX® Photopheresis Systems (ECP) in pediatric participants with steroid-refractory aGvHD. The study is composed of Screening, Treatment, and Follow-up Periods.

Phase:

Phase 3

Details

Lead Sponsor:

Mallinckrodt
Therakos, Inc., a Mallinckrodt Company

Treatments:

Methoxsalen
Pharmaceutical Solutions